Document:

<Page>

                                                                   Exhibit 10.11

    Confidential materials omitted and filed separately with the Securities and
                           Exchange Commission. Asterisks denote such omission.

                             FIRST AMENDMENT TO THE
                       COLLABORATION AND LICENSE AGREEMENT

          This FIRST AMENDMENT TO THE COLLABORATION AND LICENSE AGREEMENT
("Amendment"), is between DYAX CORP., a Delaware corporation, having a principal
place of business at One Kendall Square, Bldg. 600, Cambridge, Massachusetts
02139 ("Dyax"); and BRACCO HOLDING, B.V., a Netherlands corporation, having its
principal place of business at Strawinskylaan 3051, 1077 ZX Amsterdam, and
BRACCO INTERNATIONAL, B.V., a Netherlands corporation, having its principal
place of business at Strawinskylaan 3051, 1077 ZX Amsterdam ("Bracco"). Dyax and
Bracco may be referred to as each as a "Party" or collectively as the "Parties".
The Parties hereby agree as follows:

                                    RECITALS

          WHEREAS, the Parties have previously executed a COLLABORATION AND
LICENSE AGREEMENT ("Agreement"), effective October 31, 2000;

          WHEREAS, the Parties wish to extend the Research Term of the Agreement
by another three years;

          WHEREAS, the Parties wish to amend selected portions of the Agreement
in light of the extension.

          NOW, THEREFORE, in consideration of the foregoing and the covenants
and premises contained in this Amendment, the Parties hereto hereby agree to the
following amendments to the Agreement:

                                   AMENDMENTS

     Article 2, Section 2.1.c. is hereby amended to recite:

          2.1.c.  DYAX ROLE DURING THE RESEARCH TERM. During the Research
Term, Dyax will assign [*****] Dyax full time equivalent employees ("FTE"s)
(including space and material supplies for such FTEs) to provide research and
technology transfer in connection with Collaboration Projects. The parties
envision that the Dyax FTEs will be used in Collaboration Projects during the
Research Term: (1) to optimize and develop Dyax Leads; (2) to screen the Dyax
libraries to identify and optimize Collaboration Leads for IN VIVO diagnostic
Targets; (3) to build and screen custom libraries as may be necessary; (4) to
provide training and assistance to designated Bracco scientists on the use of
Dyax Technology; (5) to extend work on Dyax Leads or Collaboration Leads to
the Bracco Therapeutics Field in accordance with any extension of Bracco's
license rights. At any time after January 1, 2004 during the Research Term
with 90 days notice to Dyax, Bracco may request that Dyax increase the number
of assigned Dyax FTEs, of which such request must be in writing if the total
expenditure of $[*****]/year for the Dyax FTEs will be exceeded. During the
Research Term, any research and development performed by Dyax using the Dyax
FTEs shall be conducted as part of a Collaboration Project.

--------------------
Confidential materials omitted and filed separately with the Securities and
Exchange Commission. Asterisks denote such omission.

<Page>

     A New Article 4, Section 4.4.b and 4.4c are hereby added, which recite:

          4.4.b.  After January 1, 2004, during the Research Term, Dyax agrees
that it will not grant an any third party exclusive license to any of the Dyax
Technology, Dyax Improvements, Dyax Leads, Bracco Leads, Collaboration Leads or
Collaboration Results that would preclude Bracco from practicing or exercising
its rights to initiate new or continue any Collaboration Project in accordance
with the terms of this Agreement.

          4.4.c.  After January 1, 2004, Dyax agrees not to, independently or
otherwise outside of the scope of the Agreement, discover or develop, or to
license, cooperate or participate with any other third party to discover or
develop, an imaging agent for any targets which have been identified in any
existing Collaboration Project, except for targets in which Dyax has an ongoing
imaging agent research program with a third party or for targets in which Dyax
has otherwise entered into a third party agreement to discover or develop an
imaging agent before that target is identified in an existing or future
Collaboration Project.

     Article 4, Section 4.6.a is hereby amended to recite:

          4.6.a.  EXCLUSIVE LICENSE TO DYAX TECHNOLOGY DURING THE RESEARCH TERM.
Bracco shall maintain an exclusive license to the Dyax Technology in the
Diagnostic Imaging Field during the Research Term until December 31, 2003 for so
long as Bracco complies at all times with the diligence provisions set forth in
Section 5.1a., Section 5.2, Section 5.3 and in Section 5.4 to the extent Bracco
has obtained any therapeutic rights. After January 1, 2004, Bracco's license to
the Dyax Technology and Dyax Improvements in the Diagnostic Imaging Field during
the Research Term will become non-exclusive.

     Article 6, Section 6.3 is hereby amended to recite:

          6.3     RESEARCH PAYMENTS. During the Research Term, Bracco shall make
quarterly research payments to Dyax with an annual minimum of $1,300,000. Such
payments shall be based on the number of FTEs assigned to Bracco, at the rate of
$[*****] per year per each FTE assigned to Bracco. Payments shall be due within
sixty (60) days of receipt of an invoice from Dyax showing the number of FTEs
assigned to Bracco during the previous quarter. In addition, Bracco shall
reimburse Dyax for any mutually agreed upon out-of-pocket external expenses
incurred during the Research Term. Dyax shall maintain records of the FTEs
assigned to Bracco and shall require the FTEs to report on an ongoing basis the
results of their work.

     Article 12, Section 12.1 is hereby amended to recite:

          12.1    TERM. This Agreement shall come into effect as of the
Effective Date, and unless earlier terminated as provided in this Article 12,
shall remain in full force and effect until the last to expire of the parties'
respective royalty obligations under this Agreement. The Research Term shall
commence on the Effective Date and shall remain in effect until December 31,
2003. The Research Term is hereby renewed for an additional three year term
which shall be effective from January 1, 2004 until December 31, 2006. The
Parties may thereafter agree to further extend the Research Term on mutually
agreeable terms.

--------------------
Confidential materials omitted and filed separately with the Securities and
Exchange Commission. Asterisks denote such omission.

<Page>

DYAX CORP.                                  BRACCO IMAGING S.p.A.

By: /s/ Ivana Maravic-Magovcevic            By: /s/ Diana Bracco
    ------------------------------              ------------------------------
Name:  Ivana Maravic-Magovcevic             Name:  Diana Bracco
Title: Senior VP Legal                      Title: Chairman<Page>

                                                                   Exhibit 10.17

              AMENDMENT NO. 1 TO AMENDED AND RESTATED COLLABORATION
              AGREEMENT BETWEEN GENZYME CORPORATION AND DYAX CORP.

     This Amendment No. 1 (the "Amendment") to the Amended and Restated
Collaboration Agreement dated May 31, 2002 (the "Agreement") by and between
Genzyme Corporation, with its principal office at One Kendall Square, Cambridge,
Massachusetts 02139 ("Genzyme"), and Dyax Corp., with a principal office at 300
Technology Square, Cambridge, Massachusetts 02139 ("Dyax") is effective as of
September 30, 2003 ("Amendment Effective Date"). Terms not otherwise defined
herein shall have the respective meanings attributed to them in the Agreement.

     WHEREAS, Genzyme and Dyax are parties to the Agreement, pursuant to which
the parties agreed to collaborate in developing DX-88 for the treatment of
hereditary angioedema and other inflammatory diseases; and

     WHEREAS, Genzyme and Dyax now wish to modify the terms of their
collaboration and amend certain provisions of the Agreement;

     NOW, THEREFORE, in consideration of the promises and agreements set forth
herein, and for other good and valuable consideration, Genzyme and Dyax hereby
agree as follows:

1.   The parties acknowledge and agree that on June 26, 2003, Genzyme elected to
exercise its Buy-In Option. As a result, all rights and obligations of Genzyme
contained in the Agreement that are contingent upon Genzyme's exercise of its
Buy-In Option shall hereafter be deemed to be current and fully enforceable
rights and obligations.

2.   Section 1.15 of the Agreement ("Field") shall be amended and restated as
follows:

     "FIELD" shall mean any and all therapeutic uses of a Collaboration Product,
     excluding uses relating to the Surgical Product.

3.   Section 1.31 of the Agreement ("Percentage Interest") shall be amended and
restated as follows:

     "PERCENTAGE INTEREST" shall have the meaning set forth in the Operating
     Agreement. If Genzyme exercises its Buy-In Option pursuant to Section 4.2
     hereof, the Percentage Interests of the Parties shall be adjusted such that
     the Percentage Interest of Dyax shall be fifty and one one hundredth
     percent (50.01%) and the Percentage Interest of Genzyme shall be forty-nine
     and ninety-nine hundredths percent (49.99%).

4.   In Section 2.1 of the Agreement ("General"), the term "fifty percent (50%)"
in the seventh sentence of Section 2.1 shall be deleted, and the term
"forty-nine and ninety-nine hundredths percent (49.99%)" shall be inserted in
its place.

<Page>

5.   In Section 3.2 of the Agreement ("Proposals for Additional Indications"),
the last two sentences of Section 3.2 shall be deleted in their entirety and
replaced with the following:

     Genzyme hereby acknowledges and agrees that it shall have no rights with
     respect to the Surgical Product including, without limitation, the right to
     receive royalties in connection therewith.

6.   In Section 4.2 of the Agreement ("Buy-In Option"), the term "fifty percent
(50%)" in the first sentence of Section 4.2 shall be deleted, and the term
"forty-nine and ninety-nine hundredths percent (49.99%)" shall be inserted in
its place.

7.   Section 4.3.1 of the Agreement ("General"), shall be amended and restated
as follows:

     If Genzyme elects to exercise its Buy-In Option, Genzyme shall pay Dyax an
     amount equal to fifty percent (50%) of all Program Costs incurred or
     accrued after satisfaction of the Initial Funding Commitment through the
     LLC Formation Date. The Percentage Interests of Dyax and Genzyme in
     Kallikrein LLC are set forth in Section 5.1(b) of the Operating Agreement.
     In the event that either Dyax or Genzyme fails to make a capital
     contribution to Kallikrein LLC as required by this Section 4.3 and Section
     5.1(b) of the Operating Agreement, and the other Party does not elect to
     terminate this Agreement pursuant to Section 13.2.1 hereof, then the
     Percentage Interests in Kallikrein LLC and the future funding
     responsibility of the Members shall be adjusted as provided in Section
     5.1(b) of the Operating Agreement.

8.   Section 4.3.2 of the Agreement ("Initial Capital Contributions") shall be
amended and restated as follows:

     If Genzyme elects to exercise its Buy-In Option, within five (5) working
     days after the execution and delivery of the Purchase Agreement, Dyax shall
     make a capital contribution to Kallikrein LLC in an amount equal to fifty
     and one one hundredth percent (50.01%) and Genzyme shall make a capital
     contribution to Kallikrein LLC in an amount equal to forty-nine and
     ninety-nine hundredths percent (49.99%) of the Program Costs incurred by
     Kallikrein LLC from the LLC Formation Date through and including September
     30, 2003.

9.   In Section 4.5 of the Agreement ("Sale and Purchase of LLC Interest"), the
term "fifty percent (50%)" shall be deleted, and the term "forty-nine and
ninety-nine hundredths percent (49.99%)" shall be inserted in its place.

10.  In Section 13.3.2(d) of the Agreement, in the fifth line of that
sub-section, the phrase "in the event that Dyax is the non-terminating Party"
shall be deleted, and the phrase "in the event that Dyax is the terminating
Party" shall be inserted in its place.

11.  Subsidiary is no longer a Member of Kallikrein LLC, consequently, all
references to Subsidiary in the Agreement shall be deleted. All references to
"Dyax Companies" in the Agreement shall be deemed to refer only to Dyax.

<Page>

12.  Except as expressly modified hereby, the terms of the Agreement remain
unchanged and in full force and effect and shall govern and apply to all matters
contemplated by this Amendment.

     IN WITNESS WHEREOF, the parties hereto have caused this Amendment to be
executed by their respective duly authorized representatives as of the Amendment
Effective Date.

GENZYME CORPORATION                     DYAX CORP.

By:    /s/ G. Jan van Heek              By:    /s/ Henry E. Blair
       ------------------------------          --------------------------------
Name:  G. Jan van Heek                  Name:  Henry E. Blair
Title: Executive Vice President         Title: Chairman, President and Chief
                                               Executive Officer
Date:  9/30/03                          Date:  9/30/03

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00062-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00062-of-00352.parquet"}]]